Allergy/Asthma News

Eli Lilly and Company announced a net revenue increase of 26% in the first quarter of 2024 and the resubmission of its biologic license application for lebrikizumab for the treatment of atopic dermatitis, according to a press release.

Maryland lawmakers passed HB1195, or Elijah’s Law, which requires state departments to develop a set of guidelines for childcare centers to reduce the risk for anaphylactic reactions to food allergen.

Healio has compiled April’s most-read news in asthma and allergy.

In the rapidly evolving landscape of investments, it is crucial for physicians to stay informed about alternative asset classes, such as cryptocurrency.

SelectION announced positive results from its first-in-human phase 1b trial of its lead compound, a selectively-optimized peptide, for the treatment of patients with atopic dermatitis, according to a company press release.

Patients experienced fewer reactions that required epinephrine during oral immunotherapy with peanut allergen powder compared with other immunotherapy methods, according to a study published in Annals of Allergy, Asthma & Immunology.

Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.

The FDA has approved mavorixafor for treating warts, hypogammaglobulinemia, infections and myelokathexis — or WHIM — syndrome, a rare and chronic primary immunodeficiency, according to a press release from X4 Pharmaceuticals.

The FDA has accepted Dermavant Science’s supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged 2 years and older, the company announced in a press release.

Intrinsic factors such as blood type, medical history, allergies and family history contribute to the risk for developing alpha-gal syndrome, according to a study published in Annals of Allergy, Asthma & Immunology.